Evaluation of clinical outcomes of 4-factor prothrombin complex concentrate versus andexanet alfa in the treatment of intracerebral hemorrhage by Guizan Corrales, Eduardo et al.
Baptist Health South Florida 
Scholarly Commons @ Baptist Health South Florida 
All Publications 
5-2020 
Evaluation of clinical outcomes of 4-factor prothrombin complex 
concentrate versus andexanet alfa in the treatment of 
intracerebral hemorrhage 
Eduardo Guizan Corrales 
Baptist Hospital of Miami, EduardoAG@baptisthealth.net 
Radhan Gopalani 
Baptist Hospital of Miami, radhang@baptisthealth.net 
Heidi Clarke 
Baptist Hospital of Miami, heidic@baptisthealth.net 
Jonatha Kline 
Baptist Hospital of Miami, JonathanDK@baptisthealth.net 
Felipe De Los Rios La Rosa 
Baptist Hopsital of Miami; Miami Neuroscience Institute, felipedl@baptisthealth.net 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications 
 Part of the Cardiovascular Diseases Commons, Chemicals and Drugs Commons, Nervous System 
Diseases Commons, and the Pharmacy and Pharmaceutical Sciences Commons 
Citation 
Guizan Corrales, Eduardo; Gopalani, Radhan; Clarke, Heidi; Kline, Jonatha; De Los Rios La Rosa, Felipe; 
and Wolfel, Thomas, "Evaluation of clinical outcomes of 4-factor prothrombin complex concentrate versus 
andexanet alfa in the treatment of intracerebral hemorrhage" (2020). All Publications. 3528. 
https://scholarlycommons.baptisthealth.net/se-all-publications/3528 
This Conference Lecture -- Open Access is brought to you for free and open access by Scholarly Commons @ 
Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator 
of Scholarly Commons @ Baptist Health South Florida. For more information, please contact 
Carrief@baptisthealth.net. 
Authors 
Eduardo Guizan Corrales, Radhan Gopalani, Heidi Clarke, Jonatha Kline, Felipe De Los Rios La Rosa, and 
Thomas Wolfel 
This conference lecture -- open access is available at Scholarly Commons @ Baptist Health South Florida: 
https://scholarlycommons.baptisthealth.net/se-all-publications/3528 
Evaluation of clinical outcomes of 4-factor prothrombin 
complex concentrate versus andexanet alfa in the treatment of 
intracerebral hemorrhage
Eduardo A. Guizan Corrales, Pharm.D.
Baptist Hospital of Miami | PGY-1 Pharmacy Residency 
EduardoAG@baptisthealth.net
Disclosure Statement 
• Disclosure Statement: The authors whose name are listed immediately 
below certify that they do not have anything to disclose concerning 
possible financial or personal affiliations with commercial entities that may 
be referenced in this presentation
• Primary Investigator:
o Eduardo A. Guizan Corrales, PharmD
• Co-Investigators:
o Radhan Gopalani, PharmD, BCPS
o Heidi Clarke, PharmD, BCCCP
o Jonathan Kline, PharmD, BCCCP 
o Felipe De Los Rios La Rosa, MD, ABPN
o Tom Wolfel, PharmD, BCCCP
Objective
Compare clinical outcomes between 4-factor prothrombin complex 
concentrate (4F-PCC) and andexanet alfa when used in the 
management of life-threatening intracerebral hemorrhage (ICH) at 
Baptist Hospital of Miami
Direct Oral Anticoagulants 
• Approved for stroke prevention in AF and treatment and prevention 
of VTE and PE
• Direct thrombin inhibitor 
o Dabigatran









• Estimated over 6 million patients in the US are treated with DOACs each 
year
• Despite lower bleeding rates compared to warfarin, apixaban and 
rivaroxaban have been associated with major bleeding events in 2.1% to 
3.6% of patients
• ICH accounted for 13% of major bleeds 
• 30-day mortality rates up to 45% (4-fold increased risk of mortality)
• Thromboembolic events post bleeding events and discontinuation of DOACs
US: United States 
DOACs: Direct oral anticoagulants
ICH: Intracerebral hemorrhage
AF: Atrial fibrillation





Dresden registry (Rivaroxaban) 7.6% (35 days)
DOACs Reversal Agents 
Direct Oral Anticoagulants Antidote









*Idarucizumab: FDA approved for the reversal of the anticoagulant effect of dabigatran 
+Andexanet alfa: FDA approved for the reversal of the anticoagulant effect of apixaban and rivaroxaban 
^PCC: Off-label use for life-threatening bleeding associated with non-vitamin K antagonist anticoagulants
PCC: Prothrombin Complex Concentrates 
Andexanet alfa (Andexxa®)
• Indication: Reversal of anticoagulation in patients treated with apixaban or 
rivaroxaban
• Mechanism of action: Recombinant modified human factor Xa decoy protein that 
binds and sequesters rivaroxaban and apixaban
o Catalytically inactive (no coagulation activity) 
o Higher affinity than endogenous factor Xa
• Onset: 2-5 min
• Adverse reactions: Infusion related reaction
• US Boxed Warning: Thromboembolic risks, ischemic events, cardiac arrest and 
sudden deaths 
Dosing and Cost 
Andexanet alfa dose based on apixaban or rivaroxaban dose
FXa inhibitor FXa inhibitor last dose
Timing of FXa inhibitor last dose before andexanet
alfa initiation
< 8 Hours or Unknown ≥ 8 Hours
Apixaban
≤ 5 mg Low dose
Low dose
> 5 mg/unknown High dose
Rivaroxaban
≤10 mg Low dose
>10 mg/unknown High dose
Dose Initial IV Bolus IV Infusion
Low dose 400 mg at a rate of 30 mg/min 4 mg/min for up to 120 minutes
High dose 800 mg at a rate of 30 mg/min 8 mg/min for up to 120 minutes
Cost:  $25,000 to $50,000 per treatment 
4F-PCC (Kcentra®)
• Indication: Vitamin K antagonist reversal in patients with acute major bleeding or 
need for urgent surgery/invasive procedure
• Mechanism of action: Increases plasma levels of the vitamin K dependent 
coagulation factors II, VII, IX, X, as well as proteins C and S
• Dose: 25 to 50 units/kg depending on indication
• Onset: unknown in DOAC patients 
• Adverse reactions: Hypotension, tachycardia, and thromboembolic events
• Dosage form: 500 unit and 1000 unit Kit
• Cost: ~ $5,000-$10,000 per dose 
Oral Xa Inhibitor Reversal-Guidelines
Critical Care Guidelines
ICH Management 2016
American College of Cardiology 
Expert Consensus Decision
Pathway 2017 / Updated 2018
Anticoagulation Forum 
Guidance Document 2019
Suggest administering a 4F-PCC (50 
units/kg) if ICH (Conditional 
recommendation, low quality evidence)
Updated 2018 – 1st line andexanet alfa 
(when available) for rivaroxaban and 
apixaban
If andexanet alfa not available, 
administer 4F-PCC 50 units/kg
Rivaroxaban and apixaban major 
bleeding → Suggest andexanet alfa; if 






Schulman et al. 
N=66
Majeed et al. 
N=84
Anticoagulant Xa inhibitors Xa inhibitors Xa inhibitors







Age, yrs 77.4 ± 10.8 76.9 ± 10.4 75 ± 10.9
Intracranial hemorrhage — no, (%) 227 (64) 36 (55) 59 (70)
Efficacy endpoint met — no, (%) 204 (82) 56 (85) 58 (69.1)
Thromboembolism — no, (%) 34 (10) 5 (7.6) 3 (4)
Mortality — no, (%)







Abbreviations: S = Safety E = Efficacy
No comparative trials of 4F-PCC vs andexanet alfa have been conducted
Study Rationale
• No head to head trial of andexanet alfa versus 4F-PCC
Lack of clinical data comparing DOAC reversal agents 
• Hemostatic effectiveness 
Efficacy
• Risk of thromboembolism or death
• High cost of andexanet alfa compared to 4F-PCC  
Safety concerns and cost implications 
Research Setting
• Baptist Hospital of Miami is one of the 11 hospitals that make up Baptist Health, a 
not-for-profit healthcare organization
o Total Beds: 728
o Average Daily Census: ~500 patients
• Certified as a Comprehensive Stroke Center by The Joint Commission
o 16-bed neurocritical care
o 8-bed neurocritical care unit stepdown
o 40-bed neuroscience inpatient unit
Study Design
• IRB-exempt, performance improvement, single center, 
retrospective, observational chart review 
• The study analyzed electronic medical administration records 
from August 1, 2018 to March 30, 2020 
• Subjects were divided in two groups based on the reversal 
agent received for the intracerebral hemorrhage induced by 
rivaroxaban or apixaban 
IRB: Institutional Review Board 
Study Selection 
• Inclusion Criteria
oAdults 18 years of age and older admitted at Baptist Hospital of 
Miami
oDiagnosis of ICH by brain CT scan
oRivaroxaban or apixaban therapy prior to onset of bleeding
oReceived 4F-PCC or andexanet alfa for emergent reversal of ICH 
oGCS > 7 and estimated intracerebral hematoma < 60 mL per CT or 
MRI scan
4F-PCC: 4-Factor Prothrombin Complex Concentrate
ICH: Intracerebral hemorrhage 
GCS: Glasgow coma score




• Bleeding expansion at 24 hours and 48 hours after administration of 4F-PCC 
or andexanet alfa
Secondary endpoint
• Dose of the reversal agent
• Administration in relation to last DOAC dose
• Thromboembolic events within 30 days
• Hospital length of stay
• In hospital mortality rate and discharge status 
4F-PCC: 4-Factor Prothrombin Complex Concentrate
DOACs: Direct oral anticoagulant 
Statistical Analysis 
• Nominal data presented as mean and percentages 
• Baseline characteristics as well as primary and secondary 
outcomes were compared using the fisher exact test (nominal 
data) and student’s t test (continuous data)
• P values < 0.05 were considered statistically significant 
4F-PCC: 4-Factor Prothrombin Complex Concentrate








Age — average years, (range) 82 (71-87) 79 (61-88) NS
Males sex — n, (%) 5 (71) 8 (67) NS
Indication for anticoagulation — n, (%)
Non-valvular atrial fibrillation 5 (71) 12 (100) NS
Venous thromboembolism 2 (29) 0 NS
Factor Xa inhibitor
Apixaban — n, (%) 4 (57) 11 (92) NS
Apixaban dose — average, mg 7.5 7.7 NS
Rivaroxaban — n, (%) 3 (43) 1 (8) NS
Rivaroxaban dose — average, mg 16.7 20 NS







Types of hemorrhage and Prognostic Scores 
SDH — n, (%)
Surgical — n, (%)










ICH — n, (%)
Surgical evacuation — n, (%)
EVD placement— n, (%) 
ICH score — average
ICH volume mL, average (range) 



















Laboratory results at presentation
INR — average 1.2 1.2 NS
CrCl < 30 ml/min — n, (%) 2 (29) 4 (29) NS
NIHSS — average 11.6 8.08 NS



























ICH Volume Over Time 


























SDH Thickness Over Time 
Baseline 24 hours 48 hours
• Andexanet alfa patients had 0% expansion of bleeds in non-surgical patients 
• 4F-PCC patients had 30% expansion of bleeds in non-surgical patients (all SDH) 
p=0.007 p=0.08
ICH: Intracerebral hemorrhage 
SDH: Subdural hematoma 






































Dose of reversal agent — average Low dose – 6
High dose – 1
30 units/kg -
Administration in relation to last DOAC dose —
average hours, (Range)
13 (3-26) 13 (6-22) 0.91
Thromboembolic events within 30 days — n, (%)
Aminocaproic acid — n










Hospital length of stay — average days, (range) 13 (4-39) 13 (2-27) 0.98
In hospital mortality rate — n, (%)
SDH — n










Discharge Status — n 
Home 












• Single center, retrospective chart review 
oRelied on various healthcare professional documentation 
• Sample size insufficient to meet statistically significant results
• Study was not randomized 
Conclusion
• Andexanet alfa treated patients had 0% expansion at 24 hours and 48 
hours versus 3/10 (30%) in 4F-PCC treated patients 
• Subdural hematoma: p=0.007
• Intracerebral hemorrhage: p=0.08
• Andexanet alfa treated patients had 0% thromboembolic rates versus 
25% in 4F-PCC treated patients (p=0.26)
• Overall mortality rate for andexanet alfa was 14% versus 25% in 4F-PCC 
group (p=0.50)
Assessment Questions
What is the major safety concern of 4F-PCC and andexanet alfa when 
used in the emergent reversal of life-threatening ICH? 
Arterial and venous thromboembolic events
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